Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept

阿托维亚治疗公司宣布完成9000万美元C轮融资，以推进ATTOBODY项目通过临床概念验证。

Series C round led by Deep Track Capital with participation from additional new and existing investors

C轮融资由Deep Track Capital领投，其他新投资者和现有投资者也参与其中。

Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multiple earlier-stage multi-specific programs

融资将用于ATTO-1310在慢性瘙痒症和ATTO-3712在特应性皮炎的早期至中期临床研究，以及多个更早期的多特异性项目。

SAN CARLOS, Calif., April 15, 2025-- Attovia Therapeutics, a privately-held, clinical-stage biopharma company developing treatments for immune-mediated diseases with high unmet patient need, today announced the close of a $90 million Series C financing. The funding round was led by Deep Track Capital with participation from new investors including Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, and ongoing support from existing investors including Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, and Illumina Ventures.

加利福尼亚州圣卡洛斯，2025年4月15日——Attovia Therapeutics是一家私人持有的临床阶段生物制药公司，专注于开发治疗免疫介导疾病的疗法，以满足患者高度未满足的需求。该公司今日宣布成功完成了一轮9000万美元的C轮融资。本轮融资由Deep Track Capital领投，新投资者包括Vida Ventures、赛诺菲风险投资、Mirae Asset Capital Life Science，同时获得了现有投资者的持续支持，包括Frazier Life Sciences、venBio、高盛另类投资、Nextech Ventures、Cormorant Asset Management、EcoR1 Capital、Marshall Wace和Illumina Ventures。

In conjunction with the financing, Rebecca Luse, Managing Director at Deep Track Capital, will join the Company's Board of Directors..

作为融资的一部分，Deep Track Capital的董事总经理丽贝卡·卢斯将加入公司董事会。

Proceeds from the financing, along with the Company’s existing cash and investments, will be used to advance Attovia’s lead assets, ATTO-1310 and ATTO-3712, through clinical proof-of-concept, with the aim of achieving best-in-disease efficacy for the treatment of chronic pruritus and atopic dermatitis.

融资所得连同公司现有的现金和投资将用于推动Attovia的主要资产ATTO-1310和ATTO-3712完成临床概念验证，目标是实现治疗慢性瘙痒和特应性皮炎的最佳疾病疗效。

The funds will also enable focused expansion of Attovia’s pipeline of multi-specific therapeutic candidates utilizing the company’s proprietary ATTOBODY technology to develop breakthrough treatment options for patients suffering from immune-mediated disorders, including inflammatory bowel disease (IBD) and others..

这笔资金还将有助于推动Attovia公司利用其专有的ATTOBODY技术，专注于扩展多特异性治疗候选药物的管线，为患有免疫介导疾病（包括炎症性肠病（IBD）等）的患者开发突破性治疗方案。

“Completing what was an oversubscribed round of financing during this time speaks to the standout potential of our platform, programs, and excellent team,” said Tao Fu, Attovia’s founder and CEO. “We deeply appreciate the support of our exceptional investor base and the shared commitment to transforming the lives of patients living with immune-mediated diseases.

“在这个时期完成这轮超额认购的融资，充分说明了我们的平台、项目和优秀团队所具有的巨大潜力，”Attovia创始人兼首席执行官傅涛表示。“我们深深感谢卓越投资者群体的支持，以及共同致力于改变免疫介导疾病患者的生活。

We now have a multi-year runway to advance our programs expeditiously, expand our pipeline judiciously, and pursue potential partnerships, all of which should give us greater optionality for the future.”.

我们现在有多年的空间，可以快速推进我们的项目，审慎地扩展我们的产品线，并寻求潜在的合作伙伴关系，所有这些都应该让我们在未来拥有更多的选择权。"

The financing allows Attovia to continue to advance its first ATTOBODY-based product candidate, ATTO-1310, a first-in-class, half-life extended anti-IL31 biologic, currently in Phase 1 studies, to provide a highly efficacious, fast acting, and convenient treatment option for chronic pruritus of unknown origin (CPUO)—a disease affecting millions of patients in the U.S.

这笔融资使得 Attovia 能够继续推进其首个基于 ATTOBODY 的候选产品 ATTO-1310，这是一种首创的、半衰期延长的抗 IL31 生物制剂，目前正在进行一期临床试验，为原因不明的慢性瘙痒症（CPUO）提供一种高效、快速和便捷的治疗选择——这一疾病影响着美国数百万患者。

and other developed countries with currently no approved treatments—as well as additional pruritic conditions with urgent unmet need..

以及其他目前尚无批准治疗的发达国家——以及更多存在迫切未满足需求的瘙痒症状。

Attovia is also advancing ATTO-3712, a first-in-class anti-IL13 x IL31, half-life extended bispecific designed to provide breakthrough efficacy and convenient dosing in atopic dermatitis and potentially chronic spontaneous urticaria, prurigo nodularis, and other inflammatory skin conditions. The company plans to start Phase 1 clinical studies with ATTO-3712 in the second half of 2025..

Attovia公司还在推进ATTO-3712的研发，这是一种首创的抗IL13 x IL31半衰期延长的双特异性抗体，旨在为特应性皮炎以及潜在的慢性自发性荨麻疹、结节性痒疹和其他炎症性皮肤病提供突破性的疗效和便捷的给药方式。该公司计划在2025年下半年启动ATTO-3712的I期临床研究。

Attovia’s earlier-stage pipeline includes ATTO-004, a multi-specific drug candidate targeting IBD, and two other multi-specific discovery-stage programs.

阿托维亚较早期的管线包括针对IBD的多特异性候选药物ATTO-004，以及另外两个多特异性发现阶段的项目。

“Attovia has created a transformative pipeline leveraging its revolutionary ATTOBODY platform,” said Rebecca Luse, Managing Director at Deep Track Capital. “We are highly impressed with the team's speed and quality of disciplined execution, and we are looking forward to supporting their growth and success as they work to realize the full potential of their platform and pipeline programs.”.

“Attovia 利用其革命性的 ATTOBODY 平台打造了一条变革性的管线，”Deep Track Capital 董事总经理 Rebecca Luse 表示。“团队高效且纪律严明的执行力给我们留下了深刻印象。我们期待支持他们的成长与成功，因为他们正致力于充分释放平台和管线项目的潜力。”

About Attovia

关于Attovia

Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics.

Attovia 正在开发一条用于治疗免疫介导疾病的生物治疗产品管线。我们利用自主研发的生物平台 ATTOBODY™，生成潜在的首创和最佳多特异性药物。

ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multi-specific biologics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients.

ATTOBODIES利用空间定位技术实现双位点靶向结合。ATTOBODIES的双位点结合模式带来了超高亲和力，从而转化为同类最佳的生物活性效力。ATTOBODIES提供无限制的工程设计，是开发多特异性生物制品的理想平台，其可调节的半衰期使得在患者中有望实现每季度或更低频率的给药。

The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice. Learn more at www.attovia.com and follow us on LinkedIn..

高通量、基于进化的ATTOBODY发现平台以行业领先的速度提供高度多样性，加速并降低治疗开发的风险，有望成为下一代首选模式。更多信息请访问www.attovia.com，并在LinkedIn上关注我们。

Contact:

联系：

Press Contact

媒体联系人

Attovia Therapeutics:

阿托维亚治疗学：

info@attovia.com

info@attovia.com